ObsEva initiated with an Overweight at JPMorgan. JPMorgan analyst Eric Joseph started ObsEva with an Overweight rating and $29 price target. The analyst views ObsEva as an “underappreciated, emerging clinical-stage player” in the women’s health space. The company has two pivotal stage assets addressing “significant commercial opportunities, and wholly owned rights in major markets,” Joseph tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.